Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch

Dow Jones

Jun 08

By Dominic Chopping

Novo Nordisk said prescriptions for its Wegovy weight-loss pill have surpassed three million since launching in early January.

The Danish drugmaker said late Sunday that the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, with a further two million prescriptions achieved in the following 10 weeks.

More than 80% of new prescriptions filled for the Wegovy pill are for patients new to the GLP-1 class of drugs, which the company says indicates that the new oral formulation is expanding the obesity treatment market, rather than replacing existing injectable therapies.

Having initially launched the Wegovy pill in the U.S., Novo Nordisk last week announced the drug's launch in the United Arab Emirates and it said it is preparing further launches in the second half of the year.

The drugmaker has also recently launched a higher-dose Wegovy weight-loss shot, and it said the drug has also demonstrated strong uptake in the early days of availability.

Wegovy HD is a once-weekly injection that contains 7.2 milligrams of active ingredient semaglutide, which the company has said offers the highest weight-loss of any Wegovy injection so far.

Prior to the launch of Wegovy HD, the highest available injectable dose was 2.4 milligrams of semaglutide.

Write to Dominic Chopping at dominic.chopping@wsj.com

(END) Dow Jones Newswires

June 08, 2026 02:18 ET (06:18 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2641062701"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2641062701\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2641062701?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 14:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641062701","market":"nz","top_or_hot":-1,"title":"Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dominic Chopping \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> said prescriptions for its Wegovy weight-loss pill have surpassed three million since launching in early January. \n</p>\n<p>\n  The Danish drugmaker said late Sunday that the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, with a further two million prescriptions achieved in the following 10 weeks. \n</p>\n<p>\n  More than 80% of new prescriptions filled for the Wegovy pill are for patients new to the GLP-1 class of drugs, which the company says indicates that the new oral formulation is expanding the obesity treatment market, rather than replacing existing injectable therapies. \n</p>\n<p>\n  Having initially launched the Wegovy pill in the U.S., Novo Nordisk last week announced the drug's launch in the United Arab Emirates and it said it is preparing further launches in the second half of the year. \n</p>\n<p>\n  The drugmaker has also recently launched a higher-dose Wegovy weight-loss shot, and it said the drug has also demonstrated strong uptake in the early days of availability. \n</p>\n<p>\n  Wegovy HD is a once-weekly injection that contains 7.2 milligrams of active ingredient semaglutide, which the company has said offers the highest weight-loss of any Wegovy injection so far. \n</p>\n<p>\n  Prior to the launch of Wegovy HD, the highest available injectable dose was 2.4 milligrams of semaglutide. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 08, 2026 02:18 ET (06:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-08 14:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dominic Chopping \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> said prescriptions for its Wegovy weight-loss pill have surpassed three million since launching in early January. \n</p>\n<p>\n  The Danish drugmaker said late Sunday that the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, with a further two million prescriptions achieved in the following 10 weeks. \n</p>\n<p>\n  More than 80% of new prescriptions filled for the Wegovy pill are for patients new to the GLP-1 class of drugs, which the company says indicates that the new oral formulation is expanding the obesity treatment market, rather than replacing existing injectable therapies. \n</p>\n<p>\n  Having initially launched the Wegovy pill in the U.S., Novo Nordisk last week announced the drug's launch in the United Arab Emirates and it said it is preparing further launches in the second half of the year. \n</p>\n<p>\n  The drugmaker has also recently launched a higher-dose Wegovy weight-loss shot, and it said the drug has also demonstrated strong uptake in the early days of availability. \n</p>\n<p>\n  Wegovy HD is a once-weekly injection that contains 7.2 milligrams of active ingredient semaglutide, which the company has said offers the highest weight-loss of any Wegovy injection so far. \n</p>\n<p>\n  Prior to the launch of Wegovy HD, the highest available injectable dose was 2.4 milligrams of semaglutide. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 08, 2026 02:18 ET (06:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2641062701","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641062701","pubTimestamp":1780899480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk said prescriptions for its Wegovy weight-loss pill have surpassed three million since launching in early January.The Danish drugmaker said late Sunday that the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, with a further two million prescriptions achieved in the following 10 weeks.More than 80% of new prescriptions filled for the Wegovy pill are for patients new to the GLP-1 class of drugs, which the company says indicates that the new oral formulation is expanding the obesity treatment market, rather than replacing existing injectable therapies.Having initially launched the Wegovy pill in the U.S., Novo Nordisk last week announced the drug's launch in the United Arab Emirates and it said it is preparing further launches in the second half of the year.The drugmaker has also recently launched a higher-dose Wegovy weight-loss shot, and it said the drug has also demonstrated strong uptake in the early days of availability.Weg","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVOX":"2倍做多NVO ETF-Defiance","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4599":"减肥药","NVO":"诺和诺德","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4007":"制药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4588":"碎股"},"translate_title":"诺和诺德减肥药处方自上市以来已达到300万张","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.98,"NVOH":0.6,"NVOX":0.6},"content_text":"By Dominic Chopping \n\n\n \n\n\nNovo Nordisk said prescriptions for its Wegovy weight-loss pill have surpassed three million since launching in early January. \n\n\n  The Danish drugmaker said late Sunday that the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, with a further two million prescriptions achieved in the following 10 weeks. \n\n\n  More than 80% of new prescriptions filled for the Wegovy pill are for patients new to the GLP-1 class of drugs, which the company says indicates that the new oral formulation is expanding the obesity treatment market, rather than replacing existing injectable therapies. \n\n\n  Having initially launched the Wegovy pill in the U.S., Novo Nordisk last week announced the drug's launch in the United Arab Emirates and it said it is preparing further launches in the second half of the year. \n\n\n  The drugmaker has also recently launched a higher-dose Wegovy weight-loss shot, and it said the drug has also demonstrated strong uptake in the early days of availability. \n\n\n  Wegovy HD is a once-weekly injection that contains 7.2 milligrams of active ingredient semaglutide, which the company has said offers the highest weight-loss of any Wegovy injection so far. \n\n\n  Prior to the launch of Wegovy HD, the highest available injectable dose was 2.4 milligrams of semaglutide. \n\n\n \n\n\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 02:18 ET (06:18 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}